CT Findings in Surgically Treated Focal Pancreatic Disease- A Retrospective Study

To retrospectively investigate CT imaging features of autoimmune and chronic pancreatitis (AIP and CP) mimicking pancreatic ductal adenocarcinoma in surgically resected patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Autoimmune Pancreatitis Autoimmune Diseases Chronic Disease Digestive System Diseases Disease Attributes Immune System Diseases Pancreatic Diseases Pancreatitis Pancreatitis, Chronic Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Definite diagnosis of autoimmune pancreatits or adenocarcinoma

Exclusion criteria

No surgery

Treatment and study plan

Computed Tomography

Diagnostic Test

Primary outcomes

Imaging features of autoimmune pancreatitis

Time frame: Time frame for each study object is the time between tumor board conference and surgery - typically 2-4 weeks

Patients with a final histopathological diagnosis of autoimmune pancreatitis is identified from pancreatic surgery database and compared with matched control groups. Imaging features available at the primary tumor board conference are evaluated blinded to the final diagnosis

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Important dates

Study start: 2010
Primary completion: 2021
Study completion: 2021
First posted: Nov 21, 2024
Registry last updated: Nov 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed